Goodwin Advises AbCellera Biologics on $200 Million Public Offering

The Life Sciences team advised AbCellera Biologics (“AbCellera”) on completing an oversubscribed underwritten public offering of 17,435,897 common shares at a public offering price of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares at a price to the public of $9.74999 per pre-funded warrant. The gross proceeds from the offering were approximately $200 million before deducting underwriting discounts and commissions and estimated offering expenses. AbCellera intends to use the net proceeds from the offering to fund the continued research, development, and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and other general corporate purposes.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more.

The Goodwin team was led by Griffin Drake, Kim De Glossop, Deepa Rich, Sam Zucker, and Candace Hagey. Steven Tjoe, Ora Grinberg, Garrett Gaughan, and Maggie Wong provided valuable assistance and advice.

For more information on the deal, please read the launch press release and pricing press release.